$BCYC
Bicycle Therapeutics PLC

2023 Q2 Form 10-Q Financial Statement

#000155837023013057 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q2
Revenue $11.40M
YoY Change 160.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.18M
YoY Change 36.2%
% of Gross Profit
Research & Development $39.72M
YoY Change 100.06%
% of Gross Profit
Depreciation & Amortization $1.645M
YoY Change 174.17%
% of Gross Profit
Operating Expenses $54.90M
YoY Change 73.3%
Operating Profit -$43.11M
YoY Change 57.92%
Interest Expense $381.0K
YoY Change -56.85%
% of Operating Profit
Other Income/Expense, Net -$9.000K
YoY Change -136.0%
Pretax Income -$43.12M
YoY Change 58.09%
Income Tax -$517.0K
% Of Pretax Income
Net Earnings -$42.60M
YoY Change 58.97%
Net Earnings / Revenue -373.81%
Basic Earnings Per Share -$1.41
Diluted Earnings Per Share -$1.41
COMMON SHARES
Basic Shares Outstanding 30.04M
Diluted Shares Outstanding 30.19M

Balance Sheet

Concept 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $340.4M
YoY Change -8.67%
Cash & Equivalents $340.4M
Short-Term Investments
Other Short-Term Assets $10.02M
YoY Change 6.02%
Inventory
Prepaid Expenses
Receivables $45.09M
Other Receivables $12.88M
Total Short-Term Assets $408.4M
YoY Change -0.02%
LONG-TERM ASSETS
Property, Plant & Equipment $33.59M
YoY Change 99.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.15M
YoY Change 138.25%
Total Long-Term Assets $45.74M
YoY Change 23.66%
TOTAL ASSETS
Total Short-Term Assets $408.4M
Total Long-Term Assets $45.74M
Total Assets $454.2M
YoY Change 1.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.250M
YoY Change 8.05%
Accrued Expenses $34.35M
YoY Change 102.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.27M
YoY Change 74.8%
LONG-TERM LIABILITIES
Long-Term Debt $30.51M
YoY Change 1.22%
Other Long-Term Liabilities $131.3M
YoY Change 3927.42%
Total Long-Term Liabilities $161.8M
YoY Change 384.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.27M
Total Long-Term Liabilities $161.8M
Total Liabilities $234.1M
YoY Change 74.56%
SHAREHOLDERS EQUITY
Retained Earnings -$412.8M
YoY Change 51.32%
Common Stock $396.0K
YoY Change 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $220.1M
YoY Change
Total Liabilities & Shareholders Equity $454.2M
YoY Change 1.95%

Cashflow Statement

Concept 2023 Q2
OPERATING ACTIVITIES
Net Income -$42.60M
YoY Change 58.97%
Depreciation, Depletion And Amortization $1.645M
YoY Change 174.17%
Cash From Operating Activities $34.10M
YoY Change -244.9%
INVESTING ACTIVITIES
Capital Expenditures $277.0K
YoY Change -102.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$277.0K
YoY Change -97.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.29M
YoY Change 6203.59%
NET CHANGE
Cash From Operating Activities 34.10M
Cash From Investing Activities -277.0K
Cash From Financing Activities 12.29M
Net Change In Cash 46.11M
YoY Change -239.16%
FREE CASH FLOW
Cash From Operating Activities $34.10M
Capital Expenditures $277.0K
Free Cash Flow $33.82M
YoY Change -346.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30191693
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29648564
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30097234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29626974
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001761612
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30191693
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29648564
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30097234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29626974
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29873893
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30585940
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Payments For Royalties
PaymentsForRoyalties
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38916
dei Entity Registrant Name
EntityRegistrantName
Bicycle Therapeutics plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
Blocks A & B, Portway Building, Granta Park
dei Entity Address City Or Town
EntityAddressCityOrTown
Great Abington, Cambridge,
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CB21 6GS
dei City Area Code
CityAreaCode
+44
dei Local Phone Number
LocalPhoneNumber
1223 261503
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
340433000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
339154000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
45090000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2045000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10023000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9022000
CY2023Q2 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
12884000
CY2022Q4 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
19162000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
408430000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
369383000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17572000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19110000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16022000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13658000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12146000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8458000
CY2023Q2 us-gaap Assets
Assets
454170000
CY2022Q4 us-gaap Assets
Assets
410609000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5250000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6472000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37262000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26452000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
29754000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20418000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
72266000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53342000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30513000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30315000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11881000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10885000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
115083000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41455000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4330000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3829000
CY2023Q2 us-gaap Liabilities
Liabilities
234073000
CY2022Q4 us-gaap Liabilities
Liabilities
139826000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
59612613
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30585940
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29873893
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
396000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
387000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
633341000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
601105000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-877000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
387000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-412763000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-331096000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
220097000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270783000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
454170000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
410609000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11397000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4378000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16293000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8238000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39720000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19854000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71931000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34138000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14788000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11824000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29276000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28783000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
54508000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
31678000
us-gaap Operating Expenses
OperatingExpenses
101207000
us-gaap Operating Expenses
OperatingExpenses
62921000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43111000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27300000
us-gaap Operating Income Loss
OperatingIncomeLoss
-84914000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54683000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
812000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
908000
us-gaap Interest And Other Income
InterestAndOtherIncome
3741000
us-gaap Interest And Other Income
InterestAndOtherIncome
1126000
CY2023Q2 us-gaap Interest Expense
InterestExpense
821000
CY2022Q2 us-gaap Interest Expense
InterestExpense
883000
us-gaap Interest Expense
InterestExpense
1629000
us-gaap Interest Expense
InterestExpense
1701000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2112000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-575000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43120000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27275000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82802000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55258000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-517000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-447000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1135000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-866000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42603000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26828000
us-gaap Net Income Loss
NetIncomeLoss
-81667000
us-gaap Net Income Loss
NetIncomeLoss
-54392000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30191693
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29648564
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30097234
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29626974
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42603000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26828000
us-gaap Net Income Loss
NetIncomeLoss
-81667000
us-gaap Net Income Loss
NetIncomeLoss
-54392000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-948000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2094000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1264000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3014000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43551000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24734000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82931000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51378000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270783000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2716000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9042000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-316000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-39064000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243163000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
165000
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12127000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8193000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-948000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42603000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
220097000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10198000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
920000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
330258000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5673000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2094000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26828000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
311392000
us-gaap Profit Loss
ProfitLoss
-81667000
us-gaap Profit Loss
ProfitLoss
-54392000
us-gaap Share Based Compensation
ShareBasedCompensation
17235000
us-gaap Share Based Compensation
ShareBasedCompensation
15871000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3202000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1039000
bcyc Non Cash Interest Expense
NonCashInterestExpense
198000
bcyc Non Cash Interest Expense
NonCashInterestExpense
271000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1616000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3683000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-52358000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9346000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-7199000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
6850000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
638000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2418000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-2054000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1343000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1341000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8416000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3209000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1867000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-789000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-15454000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2072000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
311000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
334000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12315000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49931000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2376000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14555000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2376000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14555000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14843000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
167000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
645000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15010000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
645000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
960000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2070000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1279000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65911000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
339154000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
438680000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
340433000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372769000
us-gaap Interest Paid Net
InterestPaidNet
1365000
us-gaap Interest Paid Net
InterestPaidNet
1390000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
664000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
749000
bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
2771000
bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1336000
bcyc Increase Decrease Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
-1401000
bcyc Increase Decrease Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
1209000
bcyc Advance Billings On Deferred Revenue Included In Accounts Receivable
AdvanceBillingsOnDeferredRevenueIncludedInAccountsReceivable
45000000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4004000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3120000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
340400000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42600000
us-gaap Net Income Loss
NetIncomeLoss
-81700000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26800000
us-gaap Net Income Loss
NetIncomeLoss
-54400000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-412800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, revenue recognition, share-based compensation expense, valuation of right-of-use assets and liabilities, and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p>
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
305000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
367000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
30513000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
30315000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3800000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
276100000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28014000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26973000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10442000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7863000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17572000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19110000
CY2023Q2 us-gaap Depreciation
Depreciation
1600000
us-gaap Depreciation
Depreciation
3200000
CY2022Q2 us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
1000000.0
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
31500000
CY2023Q2 bcyc Long Term Debt Including End Term Charge
LongTermDebtIncludingEndTermCharge
31500000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7131000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9928000
CY2023Q2 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
20629000
CY2022Q4 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
10859000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1911000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1068000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4680000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3125000
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1906000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
970000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1005000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
502000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37262000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26452000
CY2023Q2 bcyc Debt Instrument Prepayment Option Excess Of Outstanding Amount
DebtInstrumentPrepaymentOptionExcessOfOutstandingAmount
5000000.0
CY2023Q2 bcyc Debt Instrument End Of Term Charge Rate
DebtInstrumentEndOfTermChargeRate
0.050
CY2023Q2 bcyc Debt Instrument Additional Interest Rate Event Of Default
DebtInstrumentAdditionalInterestRateEventOfDefault
0.050
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2023Q2 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
818000
CY2022Q4 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
682000
bcyc Number Of Voter Per Share
NumberOfVoterPerShare
1
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
59612613
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8193000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5673000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17235000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15871000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11397000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4378000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16293000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8238000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
61873000
bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
95870000
bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
16293000
bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
-3387000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
144837000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
CY2022 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
12099000
CY2022 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
14463000
CY2022 bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
7103000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
61873000
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1367000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1036000
us-gaap Operating Lease Cost
OperatingLeaseCost
2693000
us-gaap Operating Lease Cost
OperatingLeaseCost
1942000
CY2023Q2 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3927000
CY2022Q2 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3213000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
8823000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
7032000
CY2023Q2 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
7470000
CY2022Q2 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
1165000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
7470000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
1206000
CY2023Q2 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
11397000
CY2022Q2 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
4378000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
16293000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
8238000
CY2016Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
50900000
CY2019Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
60300000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1100000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-900000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
803000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
328000
us-gaap Variable Lease Cost
VariableLeaseCost
1451000
us-gaap Variable Lease Cost
VariableLeaseCost
595000
CY2023Q2 us-gaap Lease Cost
LeaseCost
2170000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1364000
us-gaap Lease Cost
LeaseCost
4144000
us-gaap Lease Cost
LeaseCost
2537000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0761
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0704
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2841000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5767000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5855000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3347000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
821000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2070000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
16561000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4680000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11881000
bcyc Maximum Days Allowed For Cancellation Of Contracts Prior Written Notice
MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
P90D
bcyc Period Of Royalty Payments Agreed Under Arrangement
PeriodOfRoyaltyPaymentsAgreedUnderArrangement
P10Y
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42603000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26828000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-81667000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54392000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30191693
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29648564
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30097234
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29626974
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7709897
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5821869
us-gaap Revenues
Revenues
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2023Q2 us-gaap Noncurrent Assets
NoncurrentAssets
33594000
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
32768000

Files In Submission

Name View Source Status
0001558370-23-013057-index-headers.html Edgar Link pending
0001558370-23-013057-index.html Edgar Link pending
0001558370-23-013057.txt Edgar Link pending
0001558370-23-013057-xbrl.zip Edgar Link pending
bcyc-20230630.xsd Edgar Link pending
bcyc-20230630x10q.htm Edgar Link pending
bcyc-20230630xex10d1.htm Edgar Link pending
bcyc-20230630xex10d1001.jpg Edgar Link pending
bcyc-20230630xex10d2.htm Edgar Link pending
bcyc-20230630xex10d2003.jpg Edgar Link pending
bcyc-20230630xex10d2004.jpg Edgar Link pending
bcyc-20230630xex10d2005.jpg Edgar Link pending
bcyc-20230630xex10d3.htm Edgar Link pending
bcyc-20230630xex10d4.htm Edgar Link pending
bcyc-20230630xex31d1.htm Edgar Link pending
bcyc-20230630xex31d2.htm Edgar Link pending
bcyc-20230630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
bcyc-20230630_cal.xml Edgar Link unprocessable
bcyc-20230630_def.xml Edgar Link unprocessable
bcyc-20230630_lab.xml Edgar Link unprocessable
bcyc-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcyc-20230630x10q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending